ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: cardiovascular disease

Therapeutics for COVID-19: An update from ACR Convergence 2021

Lara C. Pullen, PhD  |  December 10, 2021

ACR CONVERGENCE 2021—Rheumatology patients who test positive for COVID-19 would benefit from early use of monoclonal antibodies, said Luis Ostrosky-Zeichner, MD, chief of the Division of Infectious Diseases, McGovern Medical School, University of Texas Health Science Center (UTHealth), Houston, in a session about effective treatment options for COVID-19. Acknowledging that the SARS-CoV-2 virus has already…

Filed under:ACR ConvergenceBiologics/DMARDsMeeting Reports Tagged with:ACR Convergence 2021COVID-19

Research on SLE, pJIA & More Highlighted in 2nd ACR Convergence 2021 Plenary Session

Samantha C. Shapiro, MD  |  December 9, 2021

Experts shined a spotlight on select abstracts of the latest rheumatology research, addressing such topics as racial disparities in the management of children with SLE, vitamin D or fish oil supplementation to prevent autoimmune disease & more.

Filed under:ACR ConvergenceConditionsMeeting ReportsPediatric ConditionsSystemic Lupus Erythematosus Tagged with:ACR Convergence 2021ACR Convergence 2021 – SLECOVID-19MIS-CPediatricpJIApolyarticular juvenile idiopathic arthritis

Update on Extrapulmonary Sarcoidosis

Lara C. Pullen, PhD  |  December 6, 2021

Neurosarcoidosis & sarcoid dermatopathology are discussed.

Filed under:ACR ConvergenceConditionsMeeting ReportsOther Rheumatic Conditions Tagged with:ACR Convergence 2021FernandezGelfand

The State of Clinical Science for Pediatric Rheumatology in 2021

Elizabeth Sloan, MD  |  December 2, 2021

ACR Convergence 2021—The Pediatric Rheumatology Year in Review began with a fascinating talk by Mara Becker, MD, MSCE, a professor of Pediatrics and vice chair of faculty at Duke University School of Medicine, Durham, N.C. Dr. Becker began by describing her search strategy to select high-yield clinical science publications in pediatric rheumatology from the past…

Filed under:ACR ConvergenceConditionsMeeting ReportsPediatric Conditions Tagged with:ACR Convergence 2021ClinicalCOVID-19JIAMultisystem Inflammatory Syndrome in Children (MIS-C)PediatricPediatric Rheumatologypolyarticular juvenile idiopathic arthritis (JIA)

The Great Debate: Belimumab vs. Voclosporin in Lupus Nephritis

Thomas R. Collins  |  December 1, 2021

ACR Convergence 2021—The Great Debate at the meeting sparked a thoughtful discussion on the future of lupus nephritis treatment strategies, with experts saying clinicians should be open to new ways of approaching patient care. In the past year, approvals of the monoclonal antibody belimumab and the calcineurin inhibitor voclosporin for use in lupus nephritis (when…

Filed under:ACR ConvergenceBiologics/DMARDsConditionsDrug UpdatesMeeting ReportsSystemic Lupus Erythematosus Tagged with:ACR Convergence 2021ACR Convergence 2021 – SLEbelimumabvoclosporin

FDA Discussed 2021 Drug Warnings & Approvals at ACR Annual Meeting

Thomas R. Collins  |  December 1, 2021

ACR Convergence 2021—The recent Boxed Warning requirement applied to three Janus kinase (JAK) inhibitors, cautioning doctors and patients about several major risks in patients with rheumatoid arthritis, came only after rigorous data collection and careful consideration of the risks and the benefits, U.S. Food & Drug Administration (FDA) officials said in November at ACR Convergence…

Filed under:ACR ConvergenceConditionsDrug UpdatesMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2021ACR Convergence 2021 – RAavacopanbaricitinibJAK inhibitorsTofacitinibupadacitinib

Joint Venture: 2021 Updates in Rheumatoid Arthritis

Jason Liebowitz, MD, FACR  |  November 24, 2021

An update on the state of RA management was presented by Dr. Bryant England, a co-author of the 2021 ACR Guideline on the Management of Rheumatoid Arthrits, during the Review Course held during ACR Convergence 2021.

Filed under:ACR ConvergenceConditionsMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2021ACR Convergence 2021 – RA

The Many Facets of COVID-19: Experts Address Basic & Clinical Research Concepts in the COVID-19 Era

Jason Liebowitz, MD, FACR  |  November 23, 2021

New concepts in autoimmunity & immunology are being discovered daily in research being conducted to understand the SARS-CoV-2 virus and its implications for rheumatology & all fields of medicine. Here are some insights shared by experts during day 1 of the Basic and Clinical Research Conference.

Filed under:ACR ConvergenceConditionsMeeting ReportsPediatric Conditions Tagged with:ACR Convergence 2021COVID-19Multisystem Inflammatory Syndrome in Children (MIS-C)U.S. Food and Drug Administration (FDA)vaccine hesitancy

Research Helps Explain Idiosyncrasies of COVID-19

Jason Liebowitz, MD, FACR  |  November 23, 2021

The Basic and Clinical Research Conference session on Rheumatology Complications of Emerging Viral Infections/SARS-CoV-2 presented findings from numerous studies that help explain some of the idiosyncrasies of COVID-19.

Filed under:ACR ConvergenceConditionsMeeting ReportsPediatric Conditions Tagged with:ACR Convergence 2021COVID-19interferonMultisystem Inflammatory Syndrome in Children (MIS-C)

Case Report: A Rare Mimic of Giant Cell Arteritis

Iryna Nemesh, MD, Saleema Kherani, MD MPH, Shikha Singla, MD, & William Wirostko, MD  |  November 14, 2021

Syphilis is a chronic sexually transmitted disease (STD) caused by the spirochete Treponema pallidum. The clinical manifestations of syphilis are divided into four stages: 1) the primary stage, characterized by painless mucosal or cutaneous chancre at the site of infection that resolves spontaneously; 2) the secondary stage in which a generalized maculopapular rash and condyloma…

Filed under:ConditionsVasculitis Tagged with:ocular diseasesyphilis

  • « Previous Page
  • 1
  • …
  • 42
  • 43
  • 44
  • 45
  • 46
  • …
  • 65
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences